Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariate and multivariate analyses for survival of squamous cell carcinoma patients

From: Prognostic significance of peripheral CD8+CD28+ and CD8+CD28− T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy

Variables Overall survival Progression-free survival
HR (95% CI) P HR (95% CI) P
A (univariate)
 Gender
  Male 1.50 (0.56–3.96) 0.414 0.97 (0.42–2.25) 0.954
  Female 1   1  
 Age (years)
  ≥ 60 0.47 (0.21–1.05) 0.069 0.49 (0.23–1.04) 0.065
  < 60 1   1  
 Smoking status
  Ever smokers 1.08 (0.46–2.56) 0.852 0.81 (0.37–1.73) 0.581
  Never smokers 1   1  
 cStage
  IV 1.22 (0.58–2.56) 0.597 1.15 (0.58–2.27) 0.681
  III 1   1  
 Tumor differentiation
  Poor 1.30 (0.58–2.91) 0.52 1.29 (0.60–2.75) 0.512
  Well/moderate 1   1  
 Performance status
  1–2 1.72 (0.72–4.06) 0.215 1.30 (0.63–2.68) 0.471
  0 1   1  
B 1.29 (0.91–2.03) 0.328 1.17 (0.96–1.82) 0.532
NK 0.97 (0.57–1.82) 0.165 0.92 (0.62–1.56) 0.181
NKT 1.19 (0.73–1.65) 0.720 1.21 (0.86–1.76) 0.824
γδT 0.65 (0.35–1.36) 0.611 0.78 (0.43–1.44) 0.955
CD8+CD28+ 1.01 (0.94–1.10) 0.749 0.99 (0.93–1.07) 0.902
CD8+CD28− 2.01 (1.16–4.05) 0.039 2.12 (1.07–4.36) 0.023
CD28+/CD28− 0.96 (0.68–1.37) 0.863 0.87 (0.61–1.22) 0.414
CD4+CD25hi 1.17 (0.68–2.04) 0.570 1.28 (0.78–2.10) 0.331
B (multivariate)
 Age (years) 0.47 (0.21–1.05) 0.064 0.48 (0.22–1.02) 0.057
 CD8+CD28− 1.41 (1.17–3.06) 0.035 2.01 (1.06–3.85) 0.029
  1. P-values for multivariate analyses are adjusted. The HR and 95% CI were reported for 1 SD increase for immune cells